Baby Formula Lawsuit 2025 | NEC Claims & Settlement Updates

The Baby Formula Lawsuit in 2025 centers on claims that cow milk-based infant formulas, primarily used in neonatal intensive care units, increased the risk of necrotizing enterocolitis in premature babies. Families allege that manufacturers failed to warn parents and medical providers about these dangers. With growing scientific evidence, rising case filings, and active litigation in federal and state courts, the lawsuit is moving toward significant developments. Parents are seeking compensation for medical costs, long-term complications, and wrongful death. This page provides updated information on NEC claims, eligibility, recent court activity, and the current outlook for potential settlements.

What the Baby Formula Lawsuit Is About

The baby formula lawsuits center on allegations that cow’s-milk–based formulas, such as certain Enfamil and Similac products, significantly increase the risk of necrotizing enterocolitis (NEC) in premature infants. Parents claim that manufacturers knew or should have known about this heightened danger but failed to provide adequate warnings to doctors, hospitals, and families.

The lawsuits argue that these companies aggressively marketed their products to NICUs and caregivers without disclosing that preterm babies face a substantially higher likelihood of developing NEC when fed milk formula. Families also contend that safer alternatives, such as human milk or donor milk, were not emphasized despite long-standing research showing their protective benefits.

Many claims involve infants who required emergency surgery, sustained lifelong complications, or tragically died from NEC. As a result, parents accuse formula makers of failing to warn, negligent marketing, and of misrepresenting the safety of their products for premature babies.

Timeline of the Baby Formula Litigation

The NEC baby formula litigation has evolved rapidly, shaped by major scientific studies, influential court rulings, and a series of high-stakes jury verdicts. This timeline outlines the key developments that have driven the lawsuits forward, revealing how new research, expanding MDLs, and state court actions continue to influence settlement pressure and future case strategy.

September 22, 2025 – Court Orders Comprehensive NEC Case Census

Judge Rebecca Pallmeyer issued a new directive designed to organize the expanding NEC baby formula litigation and prepare the MDL for eventual resolution. The updated Case Management Order No. 14 introduces a detailed census system to account for every claim, including cases in the MDL, cases filed in other courts, and unfiled client matters held by law firms.

Attorneys must complete electronic census forms through MDL Centrality. Filed MDL cases require an MDL Census Form, while cases outside the MDL and unfiled claims must use a Non-MDL Census Form. All submissions must be complete, include medical records, and be filed without objection. Deadlines are strict. MDL cases must be submitted within 30 days, with signatures provided within 60 days if not immediately available. Cases filed elsewhere or held in inventory carry 60 or 90-day deadlines, depending on the timing of retention or filing.

The order reflects concerns learned from other mass torts, where late surges of filings disrupted trial schedules and created uncertainty during settlement discussions. By gathering accurate claim counts early, the court aims to prevent similar delays and ensure that future negotiations rest on reliable data. This type of census process is standard in major MDLs and signals a push toward a more structured path to resolution.

September 2, 2025 – Abbott Signals No Interest in Settlement

During Abbott’s Q2 2025 earnings call, executives took a firm stance on the NEC litigation. CEO Robert Ford rejected the idea of settlement talks and reiterated confidence in the company’s formula products, citing support from regulators, physicians, and scientific data. He minimized the financial significance of the product line and suggested Abbott would rather withdraw it from the market than allow legal actions to influence medical decision making.

Although the tone was forceful, this type of public positioning is common in mass tort cases. Companies often project strength during earnings calls even when their long term strategy ultimately shifts toward negotiation or settlement.

August 27, 2025 – New NEC Baby Formula Lawsuit Filed

A Jacksonville, Florida, family has filed a new NEC lawsuit in the Northern District of Illinois, joining MDL 3026. The complaint alleges that their premature infant developed necrotizing enterocolitis after being fed Abbott’s bovine-based Similac products, including Similac and Similac Human Milk Fortifier. Born at 27 weeks and weighing 1,000 grams, the child received enteral feeds in the NICU and was later diagnosed with NEC, resulting in severe injuries. The lawsuit claims Abbott falsely marketed its formula as safe for preterm infants while downplaying known risks and engaging in misleading promotional practices targeting vulnerable parents and healthcare providers.

August 23, 2025 – Judge Limits Some Defense Expert Testimony

Plaintiffs scored a partial win as the MDL court restricted portions of the defense’s expert testimony. The most significant ruling involved Dr. Larry Hedges, an expert for Mead Johnson, who admitted using incorrect numerical data in a major analysis—errors that made cow-milk-based formula appear safer than it is. The judge ruled that any opinions relying on that flawed calculation are inadmissible. Other defense experts, including Dr. Makuch and Dr. Claud, will still testify, though the court noted issues with their methodology and study selection. The decision strengthens plaintiffs’ position by curbing the defense’s reliance on questionable scientific analyses.

August 16, 2025 – Second Bellwether Trial Removed From Schedule

The federal NEC formula MDL has encountered another delay after the second bellwether trial was taken off the schedule only weeks before it was set to begin. This development highlights the procedural obstacles plaintiffs face in the MDL, where the court’s focus on alternative feeding options and individualized warnings is preventing some cases from reaching a jury. At the same time, state court trials have produced major plaintiff victories, including awards of 60 million dollars and 495 million dollars, while the only defense verdict was later reversed for misconduct. This growing gap raises questions about whether the MDL is still operating as an efficient path toward resolution. Abbott’s sealed motions to exclude a causation expert and dismiss this bellwether will shape the direction of the litigation in the coming months. For now, the next scheduled trial is set for November.

August 1, 2025 – Plaintiff’s Expert Excluded and Case Dismissed

The second bellwether will not proceed to trial after the MDL judge granted summary judgment to Abbott. The court ruled that the plaintiff’s causation expert could not reliably apply her opinion to an infant of the child’s specific gestational age and weight. With this ruling, the upcoming trial date has been taken off the calendar. Although the court said it could revisit the issue if new evidence becomes available, the case is effectively closed for now. This decision reflects a growing concern among plaintiffs about the strict use of Daubert to block cases before they reach trial. The judge did not question the expert’s methods, only their exact fit to the facts, which many plaintiffs’ lawyers view as an unnecessarily narrow approach. As a result, more NEC baby formula lawsuits are being filed in state courts where juries, rather than judges, decide what causation evidence is persuasive. The dismissal also slows the MDL timeline even further, pushing the first trial to November.

July 21, 2025 – New NEC Filing in New Jersey State Court

A Kansas City family has filed a new NEC case in New Jersey state court, alleging that their extremely premature infant developed necrotizing enterocolitis after receiving cow’s milk formula while hospitalized in a New Jersey NICU. The baby, delivered at just over 27 weeks and weighing under two pounds, was fed bovine-based products made by Abbott and Mead Johnson soon after birth.

The complaint states that the infant showed early gastrointestinal symptoms, followed by an NEC diagnosis, emergency bowel surgery, and prolonged medical complications. The parents say they were never informed that cow’s milk products carry higher risks for premature infants or told that safer alternatives such as donor human milk or human milk-based fortifiers were available.

The lawsuit faults both the hospital and the manufacturers. The hospital allegedly failed to disclose risks or obtain informed consent, while the companies are accused of promoting their products for preterm infants without clear warnings despite internal knowledge and long-standing scientific concerns. The filing also highlights the influence that formula makers maintain through marketing relationships with hospitals.

Because New Jersey defendants are included and the case was filed in that state, it remains in New Jersey court rather than being absorbed into the federal MDL.

July 12, 2025 – Setback for Pennsylvania Plaintiffs

Judge Pallmeyer rejected remand in six Pennsylvania cases, ruling that plaintiffs had fraudulently joined in-state hospital defendants. Although the court had previously found that negligence claims against the hospitals had a reasonable chance of success, this time the judge based the decision on the plaintiffs’ litigation conduct rather than the legal merits. The court pointed to limited discovery, a single brief deposition, and the plaintiffs’ prior decision not to appeal the state court’s dismissal of hospital defendants as evidence that the claims were not pursued in good faith.

This approach, often described as the “no real intent” doctrine, is a controversial shortcut that allowed Abbott to avoid both the one-year removal limit and the voluntary or involuntary rule. The judge clarified that the underlying claims were still legally viable but concluded that the plaintiffs had used the hospital defendants primarily to prevent removal to federal court. This marks a significant shift away from the usual deference granted to a plaintiff’s choice of forum.

Because of the broader implications, the judge certified two questions for immediate appeal, including whether litigation conduct alone can justify fraudulent joinder. Plaintiffs are likely to welcome the chance for appellate review. Allowing courts to second-guess strategy in this way could turn fraudulent joinder into a sweeping removal tool for corporate defendants. The Seventh Circuit will now decide whether this doctrine should stand.

July 8, 2025 – Missouri Case Remains Outside the MDL

A Missouri NEC lawsuit will continue in state court after Judge Pallmeyer rejected Mead Johnson’s attempt to pull the case into the federal MDL. The company argued that a Missouri sales representative had been improperly added to defeat removal, but the judge disagreed.

The plaintiff alleges that the representative promoted Enfamil products to hospital staff while knowing or having reason to know about safety concerns for premature infants. Because Missouri law allows individual liability for employees who make misleading statements or fail to disclose product risks, the court found the claims against the representative plausible. As a result, the forum defendant rule blocked Mead Johnson from shifting the case to federal court.

The ruling underscores a strategic point for families pursuing NEC claims. Some cases are deliberately filed in state courts where local defendants can be named and where plaintiffs may have a more favorable legal structure than in the MDL. Judge Pallmeyer’s decision reinforces that pathway by confirming that sales representatives can be legitimate defendants when state law supports individual accountability.

June 10, 2025 – NEC MDL Climbs to 740 Active Cases

Updated JPML figures show that the NEC infant formula MDL now includes 740 pending lawsuits, a rise of 30 filings since last month. This steady increase mirrors the pace set in April and signals continuing momentum on the plaintiffs’ side.
Growth accelerated shortly after Judge Pallmeyer issued a significant ruling allowing the plaintiffs’ main causation experts to move forward. That decision has strengthened confidence among law firms preparing new cases as the bellwether schedule continues to take shape.
With the single state court defense verdict already overturned for improper conduct and the federal court now accepting crucial expert testimony, the litigation climate is shifting in a direction that benefits plaintiffs. At the same time, activity in multiple state courts, particularly in Missouri and Illinois, shows that attorneys are preparing on several fronts as the groundwork forms for future settlement discussions.

May 14, 2025 – Major Victory for Families in the NEC Litigation

The plaintiffs scored a significant procedural breakthrough when Judge Rebecca Pallmeyer refused to remove two central experts whose testimony supports the core allegation that cow’s milk formula meaningfully increases the risk of NEC in premature infants. The defense had sought to exclude these experts under Daubert, but the court found both reliable and relevant.

The judge concluded that pediatric epidemiologist Dr. Logan Spector was fully qualified, even though he had not previously published research focused strictly on NEC. His expertise in epidemiology and structured literature review was considered more than adequate. Spector’s analysis drew from more than two dozen studies and demonstrated a measurable rise in NEC diagnoses among preterm infants fed bovine-based formula instead of human milk. His conclusions were reinforced by separate meta-analyses prepared by biostatistician Dr. Rebecca Betensky, which reported the following increases in NEC risk:
• 67 percent in randomized trials
• 226 percent in cohort studies
• 135 percent in case-control studies

Judge Pallmeyer found that Spector’s process aligned with accepted scientific standards. He used Bradford Hill criteria, followed a transparent method for identifying and selecting studies, and even reanalyzed the data when the defense pointed out omissions. The additional studies did not alter his conclusions but instead strengthened them.

The court also upheld the testimony of neonatologist Dr. Jennifer Sucre, who explained the biological reasons premature infants are more vulnerable when fed cow’s milk products. Her assessment described how immature digestive systems react to complex animal proteins, how this environment promotes harmful bacterial growth, and how inflammatory pathways such as TLR4 activation can lead to NEC. Her evaluation drew from hundreds of studies and was presented as a comprehensive scientific overview rather than an attempt to define a precise biological pathway for each child.

The defense’s criticism that neither expert could identify an exact “dose” of cow’s milk required to cause harm carried no weight. The judge made clear that Daubert does not demand pinpoint dose thresholds, particularly in an area where controlled exposure studies would be unethical.

Because the plaintiffs’ two key experts remain in the case, the defense’s summary judgment motion was denied. The only unresolved issue concerns claims focused specifically on cow’s milk fortifiers. Those questions will be addressed later, since the first bellwether trials center solely on formula-related NEC allegations.

May 2, 2025 – First Bellwether Case Ends Before Trial

The MDL judge entered judgment for Abbott Laboratories, concluding that the evidence in this particular case did not support a finding of liability for the infant’s death after receiving Similac. The decision came just days before jury selection. This was considered one of the weaker claims in the group, so the outcome did not surprise attorneys closely watching the litigation.

April 28, 2025 – Snapshot of the Litigation and Settlement Position

The NEC Baby Formula MDL in the Northern District of Illinois now includes around 360 active federal cases. Another six to seven hundred lawsuits are playing out in state courts, particularly in Illinois, Missouri, and Pennsylvania. Altogether, the national count sits near one thousand claims. This volume is relatively small compared to mass torts such as the 3M earplug litigation, which had hundreds of thousands of filings. The more modest size of the NEC docket allows for smoother scheduling, clearer settlement modeling, and more predictable litigation management. With fewer cases and less administrative strain, the parties can more easily evaluate settlement ranges and work toward a global resolution.

March 15, 2025 – Only Defense Victory Overturned for Misconduct

A Missouri judge has invalidated the one jury verdict that had favored Abbott and Mead Johnson, ruling that the companies’ trial conduct violated court orders and tainted the proceedings. The court found that the defense repeatedly introduced barred evidence, presented arguments designed to mislead jurors, relied on improper expert statements, and attempted to shift blame without supporting proof. These violations mirrored earlier sanctions imposed on Abbott’s lead attorney for similar behavior. With the lone defense win wiped from the record and several large plaintiff verdicts already issued in other jurisdictions, the momentum in the NEC litigation has shifted firmly toward families pursuing claims.

February 11, 2025 – Defendants Seek Summary Judgment in the MDL

The formula manufacturers have asked the MDL judge to dismiss all NEC baby formula cases on the grounds that plaintiffs lack admissible expert testimony proving that cow’s milk formulas can cause necrotizing enterocolitis in premature infants. Their position is tied to their attempt to exclude the plaintiffs’ general causation experts, Dr. Logan Spector and Dr. Jennifer Sucre, under Rule 702. Without these experts, the defense argues that every claim collapses. The motion mirrors earlier arguments that courts and juries have already rejected, resulting in major plaintiff victories. In 2024, juries in Illinois and Missouri awarded $60 million and $495 million, finding that cow’s milk formulas played a role in NEC. The defense relies on select statements from NIH and federal agencies, but that does not automatically justify summary judgment. Plaintiffs are expected to highlight scientific literature and internal documents showing long-standing industry knowledge of NEC risks. A ruling that wipes out the entire MDL is theoretically possible but highly unlikely given the litigation history.

January 26, 2025 – Attempt to Bar Plaintiffs’ Neonatology Expert

The defendants have filed a motion to exclude the testimony of Dr. Jennifer Sucre, a respected neonatologist and physician-scientist from Vanderbilt University. Dr. Sucre’s work spans clinical practice and advanced research, making her one of the leading experts on preterm infant health and cellular development. Despite this, the defense claims that her primary research in lung development weakens her ability to speak on NEC. They also criticize her reliance on animal and laboratory studies, even though such research is often the only ethical way to examine disease mechanisms in premature infants. The effort to remove her appears aimed at limiting the evidence the jury will hear. Her testimony would likely be compelling, and the defendants have every incentive to keep her off the stand.

January 8, 2025 – Bellwether Trial Dates Announced

The court has scheduled the first four bellwether trials in the NEC baby formula litigation. The lineup is as follows:

1. May 5, 2025: Mar v. Abbott Laboratories, Case No. 1:22-cv-00232
2. August 11, 2025: K.B. v. Abbott Laboratories, Case No. 1:22-cv-05356
3. November 3, 2025: Brown v. Abbott Laboratories, Case No. 1:22-cv-02001
4. February 2, 2026: Inman v. Mead Johnson & Company, LLC, Case No. 1:22-cv-0373
   The schedule sets the stage for key test trials that will influence settlement discussions. The expectation is that the parties will reach a global deal before these cases proceed, but that remains uncertain.

December 13, 2024 – MDL Keeps Case From Returning to State Court

The Judicial Panel on Multidistrict Litigation has declined to remand a California NEC lawsuit back to state court, keeping it within the federal MDL in Illinois. The case involves claims that Similac and Enfamil products caused a premature infant to develop NEC shortly after being fed formula in a hospital in 2014. The child required surgery and continues to experience long-term medical complications. The panel ruled that jurisdictional objections generally do not prevent transfer to an MDL. While the federal proceedings move at a measured pace, state courts have already produced three major plaintiff verdicts, including a $495 million award in Missouri and a $60 million verdict against Mead Johnson. Because of this, many plaintiffs are evaluating whether state court filings may offer a faster path to trial.

November 21, 2024: Reflection After the First Defense Verdict

The recent win for the defense in Missouri underscores how unpredictable jury trials can be. Although this particular case did not go in the plaintiffs’ favor, it is not expected to slow the larger NEC litigation. Plaintiffs’ lawyers continue to emphasize the strength of earlier state court results, which delivered significant compensatory and punitive awards, and they remain confident in the overall direction of the litigation.

November 16, 2024: Increased Use of Donor Milk in NICUs

More neonatal intensive care units are shifting toward donor human milk for preterm infants in order to reduce the risk of NEC. This trend is driven by growing scientific evidence connecting NEC to cow-milk-based products. The ongoing litigation is also a factor, as hospitals are more cautious and aware of the potential liability concerns surrounding formula use in fragile infants.

November 1, 2024: First Missouri Defense Verdict

The defense outcome in Missouri has not altered the pace of the NEC litigation. October saw the addition of 26 new cases, bringing the number of active claims to more than 600, and state court filings continue to accelerate. State courts are currently shaping the trajectory of this litigation far more than the MDL, and that dynamic is leading more plaintiffs to pursue state-level claims. Predicting jury outcomes is impossible despite how strong a case may appear. In this trial, the defendants secured their first win in the Whitfield case even though plaintiffs’ counsel felt highly confident and sought six billion dollars in punitive damages during closing arguments.

October 31, 2024: Turbulence in the Missouri Trial

The Missouri NEC trial experienced a major disruption when the judge sanctioned Kirkland and Ellis partner James Hurst. The court barred him from introducing evidence or participating in closing arguments for the remainder of the trial. Judge Michael Noble found that Hurst repeatedly acted in bad faith and violated court orders, including attempts to present evidence that had already been restricted. The judge indicated these actions appeared to be attempts to provoke a mistrial and described the conduct as dilatory tactics that may breach Missouri’s ethical guidelines. This development suggests the defense may be concerned about how the trial is unfolding.

October 26, 2024: Defense Case Continues in the Whitfield Trial

The Whitfield trial has moved into the defense presentation. One of the key witnesses, Dr. David Stevenson, testified that he believes the child, Kaine Whitfield, may have an underlying genetic condition such as Kabuki syndrome that could account for his developmental challenges. The family maintains that his injuries stem from necrotizing enterocolitis, which they believe was triggered by cow milk formulas provided by Abbott and Mead after his premature birth. Kaine underwent extensive bowel surgery that resulted in short bowel syndrome, which affects his ability to absorb nutrients and contributes to his long-term health issues.

October 9, 2024: Status Conference Scheduled for Tomorrow

As the Whitfield trial proceeds, the NEC MDL will hold a status conference tomorrow to address several important topics.

1. The court will review a number of pending motions, including a plaintiff’s request to dismiss certain non-cancer cases without prejudice, a motion to enforce discovery obligations against L’Oréal, and multiple defense motions to dismiss that are unlikely to succeed.
2. Both sides continue working on the bellwether selection process to determine which representative cases will proceed to early trials.
3. Discovery remains a significant issue. Companies such as Strength of Nature and Namaste Laboratories have outstanding motions related to document production and protective orders. Revlon has provided a large volume of documents, which the plaintiffs are still analyzing for completeness.
4. Several second-wave defendants, including Advanced Beauty, John Paul Mitchell, and Wella Operations, have filed motions to dismiss, and the court is reviewing the corresponding briefing.
5. The parties are drafting an update to Case Management Order 10 to better track plaintiffs, especially those dismissed without prejudice, in order to simplify monitoring and potential refiling.

October 3, 2024: The “Everyone Already Knows” Defense Argument

One recurring defense position in this litigation is the claim that manufacturers did not need to issue warnings about NEC because hospitals were already aware of the risk. This rationale overlooks the fundamental purpose of warnings, which is to ensure that all individuals involved in feeding decisions are properly informed. Labels are intended for parents, caregivers, and health professionals who may not specialize in neonatal care. The argument also assumes universal and up-to-date knowledge among hospital staff, which is unrealistic. Without proper warnings, manufacturers shift the entire burden onto clinicians to identify and communicate risks without adequate support. Even when hospitals are aware of NEC concerns, a clear warning would signal the importance of weighing the benefits and risks of cow-milk-based formulas for preterm infants.

September 23, 2024: NIH Study Shows Donor Milk Reduces NEC Risk

A new National Institutes of Health–funded study published in JAMA reports that extremely preterm infants fed donated human milk had about half the rate of necrotizing enterocolitis compared with infants fed formula (4.2% versus 9%). The study followed 483 infants born before 29 weeks of gestation or weighing under 1,000 grams. Although infants receiving donor milk showed slightly slower growth, there were no meaningful differences in neurodevelopment at 22 to 26 months based on Bayley Scales testing. This research provides strong scientific support for plaintiffs by demonstrating that donor human milk offers a significantly lower NEC risk than formula for the most vulnerable infants.

September 9, 2024: Renewed Attacks on NEC Verdicts

Predictably, tort reform advocates have seized on the recent NEC baby formula verdicts in Missouri and Illinois. The Missouri case resulted in $95 million in compensatory damages and $400 million in punitive damages, while the Illinois jury awarded $60 million earlier this year. Critics have focused on attacking trial lawyers rather than addressing the underlying medical and scientific issues. Their “junk science” refrain is repeated without any substantive explanation of why the evidence is unreliable. The only argument with real weight is the concern that manufacturers may scale back or stop producing preterm formulas. It is a legitimate fear, but it cannot justify discouraging legitimate claims. The solution is simple: manufacturers must warn doctors and parents about the established NEC risks so families can make informed decisions.

August 25, 2024: Agreement Reached on First Four Bellwether Trials

The parties have reached an agreement on the order of the first four bellwether trials in the NEC MDL, subject to pending dispositive motions and with both sides reserving the right to pursue summary judgment in any of the cases. The proposed order is submitted to the court in place of competing position papers. The agreed order is:

1. Mar v. Abbott Laboratories (Case No. 1:22-cv-00232)
2. Diggs v. Abbott Laboratories (Case No. 1:22-cv-05356)
3. Etienne and Brown v. Abbott Laboratories (Case No. 1:22-cv-02001)
4. Inman v. Mead Johnson and Company (Case No. 1:22-cv-03737)
   The parties also jointly request that the August 29 status conference be conducted remotely instead of in person. Both sides confirm they are available to address any questions from the court.

August 17, 2024: Philadelphia Emerges as a Key Venue for NEC Claims

While the NEC baby formula litigation has largely unfolded in state courts and within the Illinois-based MDL, the recent St. Louis verdict has shifted attention to Missouri. Philadelphia now appears to be the next significant battleground. The jurisdiction is known to be favorable for plaintiffs, and NEC lawsuits there are not consolidated, meaning cases proceed individually rather than as a class action. A unique element in Philadelphia is that plaintiffs often sue hospitals along with Abbott and Mead Johnson, which complicates the defense strategy. Hospitals facing liability may distance themselves from manufacturers and argue that warnings from formula makers were inadequate. The first NEC trial in Philadelphia is expected to begin this spring.

July 31, 2024: Court Allows Depositions of Five Key Figures

Progress in the federal MDL continues, and plaintiffs have been granted approval to depose five individuals by August 20, 2024. They include:

• Dan Achimov, who worked on portfolio management and product innovation related to infant formulas.
• Brian Berg, a scientist involved in pre-clinical NEC research and product development at Mead Johnson.
• Craig Hadley, former head of regulatory compliance for formula and child nutrition.
• Daniel Secada, senior vice president of nutrition and an influential member of Mead Johnson’s leadership team.
• Justin Wells, a marketing executive involved in project management and potential initiatives related to alternatives to cow milk–based formula.

The court maintained the August 9 deadline for fact discovery, with only a narrow possibility of a short extension for unresolved written discovery. The decision follows disputes related to deposition scheduling and delays tied to Mead Johnson’s involvement in parallel state court litigation. The MDL court appears increasingly focused on keeping the federal cases moving, especially as more state cases reach verdicts.

July 26, 2024: Landmark Missouri Verdict Reshapes NEC Litigation

A Missouri jury delivered a stunning $495 million judgment to an Illinois child who developed necrotizing enterocolitis after being fed Abbott Laboratories’ specialized premature-infant formula. The award included $95 million in compensation and an extraordinary $400 million in punitive damages. After dismissing the earlier $40 million verdict as an outlier, Abbott and Mead can no longer claim these outcomes are flukes. Investors reacted sharply, wiping out roughly $8 billion of Abbott’s value in after-hours trading. The most alarming signal for the defense was the size of the punitive damages, suggesting jurors found Abbott’s conduct deeply troubling. This outcome is a clear warning for both Abbott and Mead that widespread settlements may now be their most sensible path forward.

July 11, 2024: First Abbott Infant Formula Trial Begins in Missouri

The first-ever trial targeting Abbott over its cow’s milk-based formula for premature infants opened in Missouri, with the plaintiff arguing that Similac products caused her daughter to develop NEC. This proceeding carries major bellwether implications for future settlement values across the NEC litigation. It comes on the heels of a similar case involving Mead Johnson, in which a jury awarded $60 million to a mother whose premature infant died after receiving Enfamil. For context, see the March 15 verdict referenced earlier in the timeline.

May 30, 2024: Newly Filed NEC Case Highlights How Old Many Claims Are

A recently filed NEC lawsuit illustrates how many of these injuries occurred decades ago. The case centers on a premature infant born at 32 weeks and six days on May 29, 2004, at Children’s Memorial Hermann Hospital in Houston. The baby, weighing under six pounds, was admitted to the NICU and fed Enfamil Premature 20, a cow’s milk-based formula. By June 1, 2004, the infant showed classic signs of NEC, including vomiting, abdominal swelling, blood in the stool, and imaging consistent with bowel pneumatosis and portal venous air. Treatment required immediate cessation of formula feeding, blood transfusions, and dual antibiotics. The infant later experienced respiratory decline and sepsis, requiring intubation from June 3 to June 7 before being transferred to Texas Children’s Hospital for continued care until discharge on July 23, 2004. The lawsuit alleges that the mother was never informed of the NEC risks associated with cow’s milk-based formula and holds the manufacturers responsible for the resulting severe complications.

April 5, 2024: Mead Johnson Adds Fresh Legal Firepower

Multiple new attorneys filed appearances for Mead Johnson in the MDL this week. It could simply be routine reshuffling, but the timing has sparked speculation. After the recent seventy-figure verdict, many believe the company is feeling the pressure and strengthening its defense bench accordingly.

March 15, 2024: Illinois Jury Issues Powerful 60 Million Dollar Warning

A jury in Illinois state court awarded sixty million dollars to the plaintiffs in an NEC lawsuit against Mead Johnson, finding that the company failed to properly warn about the NEC risks tied to its cow’s milk-based formula for premature infants. The child’s death was attributed to the lack of adequate warnings. This marks the first NEC failure-to-warn case to actually reach trial. The verdict far exceeded the plaintiffs’ request for twenty-five million dollars, signaling just how strongly the jury viewed the evidence. This ruling is expected to draw national attention to the litigation and may influence settlement expectations going forward.

November 1, 2023: Four Key Bellwether Cases Selected for Trial

Four significant bellwether cases have been chosen in the federal NEC litigation, offering the first real insight into how juries might interpret the evidence in these lawsuits. Each selected case involves either infant death or life-altering complications following NEC linked to formula feeding. Trial dates have not been scheduled yet, but proceedings are anticipated to begin in 2024. These outcomes could determine whether a broad settlement materializes or whether additional individual trials follow. If settlement talks stall after these initial cases, Judge Pallmeyer is expected to remand numerous lawsuits to courts across the country for independent trial settings.

July 11, 2023: Statute of Limitations Disputes Loom in Many NEC Claims

Statute of limitations arguments are likely to become a point of contention in several NEC lawsuits. While plaintiffs appear to hold strong legal footing in most cases, the issue will still create complex litigation battles. Recently, a San Francisco Superior Court judge tentatively granted Abbott’s motion to dismiss sixteen NEC formula lawsuits, though parents were given an opportunity to amend and refile their complaints. Plaintiffs’ attorneys insist that the two-year filing window should begin only when families discover the potential connection between NEC and cow’s milk-based formulas. This position aligns with longstanding fairness principles that prevent penalizing families for information that was never disclosed to them.

April 1, 2023: Emory Study Highlights Heightened NEC Risk for Black Infants

A new Emory University study confirmed a troubling trend: premature African-American infants face significantly higher rates of NEC and NEC-related fatalities than their white counterparts. This mirrors what attorneys have long observed among clients pursuing NEC claims. The study points to healthcare disparities, including unequal access to donor milk, which may contribute to higher NEC incidence in marginalized communities. In the broader litigation, twelve cases have been selected for early discovery—four chosen by plaintiffs, four by defendants, and four randomly by the court. From these, each side will later nominate two cases for initial bellwether trials.

July 27, 2022: JAMA Pediatrics Study Reinforces Need for Clear Warnings

A study published in JAMA Pediatrics underscores the severity of NEC, identifying it as one of the leading causes of death among premature infants. The research revealed that a diagnosis of NEC increases a preemie’s risk of death sevenfold. For survivors, long-term consequences are common, with many facing lifelong disabilities and extensive medical treatment. These findings strongly support plaintiffs’ arguments that parents should have received clear warnings about the risks associated with certain infant formulas.

July 19, 2022: AAP Releases Updated Infant Feeding Guidance

In response to rising concerns about NEC and the use of cow’s milk-based infant formulas, the American Academy of Pediatrics issued new recommendations advising parents to avoid formula for newborns whenever possible. The guidance also urges hospitals to discontinue promoting formula products and prioritize education on the benefits of breastfeeding.

April 8, 2022: Federal MDL for NEC Baby Formula Cases Approved

The Judicial Panel on Multidistrict Litigation has officially created a new MDL for NEC infant formula lawsuits. All federal cases will now be transferred to Judge Rebecca Pallmeyer in Illinois. Centralizing the litigation is expected to streamline proceedings and move the cases toward trial, increasing pressure on Abbott and Mead to consider realistic settlement discussions.

April 6, 2022: Illinois Supreme Court Consolidates Twenty NEC Lawsuits

The Illinois Supreme Court has allowed roughly twenty NEC-related infant formula cases to be consolidated before Judge Dennis Ruth in Madison County, forming a state-level mini-MDL. Abbott is now seeking to move the consolidated cases to Cook County or Lake County under the doctrine of inconvenient forum. This matters nationwide because NEC cases filed in other states may ultimately end up in Illinois state court, even if families hire attorneys outside the region.

February 14, 2022: Mead Johnson Backs Abbott’s Push for Federal Class Action

Mead Johnson, the maker of Enfamil, has joined Abbott in requesting that all NEC-related formula lawsuits in federal court be organized into a single class action. Both companies favor the federal court in Connecticut, though plaintiffs strongly prefer the Northern District of Illinois because both manufacturers are based near Chicago. The debate over venue remains a key early battleground in the litigation.

February 3, 2022: Possible Parallel Class Action in Illinois State Court

Attorneys are awaiting a ruling from the Illinois Supreme Court on whether a separate state court class action will be authorized for NEC formula cases. If approved, Illinois could host both a state and a federal class action at the same time. Defendants are expected to agree to such consolidation, just as they did in the federal MDL.

January 27, 2022: New Research Reinforces Plaintiffs’ Claims

Recent medical literature continues to validate plaintiffs’ arguments in the NEC infant formula lawsuits. The latest study highlights the significant risks premature infants face when fed cow’s milk-based formulas, further strengthening the scientific foundation underlying the litigation.

Health Risks & Injuries Linked to Baby Formula (NEC, Toxic Ingredients)

Parents filing NEC baby formula lawsuits report that premature infants faced serious, sometimes life-threatening complications after being fed cow–milk–based products. The most significant concern is necrotizing enterocolitis, a dangerous gastrointestinal disease that causes inflammation, infection, and the potential destruction of intestinal tissue. Babies who develop NEC often require emergency surgery, long hospital stays, and may suffer long-term digestive problems, growth delays, or neurological issues.

Families also raise concerns about harmful or unwanted ingredients sometimes found in commercial formulas, such as contaminants, heavy metals, or additives that may be difficult for medically fragile infants to digest. For preterm babies whose systems are not fully developed, these risks are magnified.

The lawsuits highlight that many parents were not warned about the increased danger of NEC from cow’s-milk formula or the availability of safer alternatives, such as human milk or donor milk. As a result, the injuries reported in these cases include intestinal perforation, sepsis, long-term disability, and, in some heartbreaking situations, loss of life.

Who Can Join the Baby Formula Lawsuit & How to File a Claim

Families may qualify to join the baby formula lawsuit if their premature infant developed necrotizing enterocolitis, also known as NEC, after being fed cow’s milk based formulas in the NICU or at home. This includes products from major manufacturers that were commonly given to preterm babies. Parents whose children experienced serious complications such as intestinal damage, surgery, long-term health problems, or death are often eligible to pursue a claim.

To begin the process, families usually speak with an attorney who handles NEC or baby formula related cases. The lawyer will review medical records, identify the formula products that were used, and determine whether the child’s injuries match the type of claims being filed across the country. After the case is evaluated, the attorney prepares and submits the claim on behalf of the family so it becomes part of the larger coordinated litigation.

Most families do not have to appear in court personally. The legal process is designed to reduce the burden on parents so they can focus on their child’s care while still seeking accountability and compensation.

Settlement Status & Compensation Outlook in the Baby Formula Lawsuit

The baby formula lawsuits involving NEC remain in active litigation, and no global settlement has been announced. Hundreds of cases have been filed in both federal and state courts, and many more are still being investigated. Judges overseeing the litigation are moving the cases through early discovery and selecting bellwether trials that will help determine how future claims may be valued. These trial outcomes often play a major role in shaping settlement talks.

Although compensation varies from case to case, families may be eligible for financial recovery related to medical bills, surgery costs, long-term care, pain and suffering, and wrongful death damages in the most tragic cases. Attorneys following the litigation believe that settlement values will depend heavily on the severity of the child’s injuries and the evidence presented in early trials. While no specific payout amounts are confirmed, the overall outlook suggests that significant compensation may be possible once the first test trials begin to influence negotiations.

Legal Strategies, Court Decisions & What They Mean for Parents

Attorneys representing families in the baby formula lawsuits are focusing on internal company documents, scientific research, and expert testimony to show that manufacturers knew or should have known that their cow milk-based products could increase the risk of NEC in premature infants. Lawyers are also working to prove that safer alternatives were available and that parents and medical providers were not given adequate warnings about these risks. These strategies aim to establish liability and strengthen each family’s claim.

Courts handling the litigation have allowed many of these claims to move forward. Judges have approved coordinated discovery, set schedules for case development, and selected early test cases that will help shape the direction of the lawsuits. These decisions are important for parents because they show that the courts recognize the seriousness of the allegations and are giving families a pathway to seek accountability. As the litigation progresses, each ruling will continue to influence how quickly cases move and how strong the claims may become.

For parents considering a claim, these legal developments provide clarity and direction. The progress in court suggests that families have a meaningful opportunity to pursue justice for the harm caused to their children.

What Comes Next in the Baby Formula Lawsuit

The baby formula litigation is expected to move into deeper discovery, where both sides exchange documents, expert reports, and additional evidence. This stage will help determine how much the manufacturers knew about the risks of NEC and whether they took steps to protect infants who relied on their products. As more information becomes available, the strength of the claims will become clearer.

Courts will also continue preparing early test cases. These trials are important because they help establish how juries may respond to the evidence. The results can influence future settlement negotiations and shape the overall direction of the litigation. Families may start to see more defined timelines for potential resolutions as these early cases progress.

Parents can expect ongoing updates as discovery unfolds, expert opinions are presented, and courts make additional rulings. All these developments will play a key role in determining possible compensation, settlement discussions, and the long term outcome of the lawsuit.

Frequently Asked Questions (FAQs) About the Baby Formula Lawsuit